用于转移性神经母细胞瘤PET成像的无载体添加的[I]碘苄胍的放射性合成。

Radiosynthesis of no-carrier-added -[I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma.

作者信息

Green Michael, Lowe Jonathan, Kadirvel Manikandan, McMahon Adam, Westwood Nigel, Chua Sue, Brown Gavin

机构信息

Wolfson Molecular Imaging Centre, University of Manchester, Manchester, M20 3LJ UK.

Cancer Research UK, Angel Building, London, EC1V 4AD UK.

出版信息

J Radioanal Nucl Chem. 2017;311(1):727-732. doi: 10.1007/s10967-016-5073-1. Epub 2016 Oct 24.

DOI:10.1007/s10967-016-5073-1

PMID:28111488

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5219010/

Abstract

-iodobenzylguanidine (IBG) has been radiolabelled at the no-carrier-added level with [I] for a proof of concept study to assess the diagnostic accuracy of [I]IBG PET/CT in detecting metastatic deposits in patients diagnosed with metastatic neuroblastoma. Radiolabelling of IBG was achieved via the iododesilylation reaction between [I]sodium iodide and -trimethylsilylbenzylguanidine. [I]IBG was produced in 62-70 % radioiodide incorporation yield from [I]sodium iodide. The average amount of formulated [I]IBG was 359 MBq (range 344-389 MBq) with an average specific radioactivity of 4.1 TBq μmol (range 1.8-5.9 TBq μmol) at end of synthesis.

摘要

已使用[I]在无载体添加水平对碘苄胍（IBG）进行放射性标记，用于一项概念验证研究，以评估[I]IBG PET/CT在检测诊断为转移性神经母细胞瘤患者的转移灶方面的诊断准确性。通过[I]碘化钠与-三甲基硅基苄基胍之间的碘脱硅反应实现IBG的放射性标记。由[I]碘化钠产生的[I]IBG的放射性碘掺入产率为62%-70%。合成结束时，配制的[I]IBG的平均量为359 MBq（范围344-389 MBq），平均比活度为4.1 TBq/μmol（范围1.8-5.9 TBq/μmol）。